PF-07799544 for Healthy Volunteers

This trial aims to determine how the new medicine, PF-07799544, moves through and exits the body. The medicine is administered in two ways: orally and intravenously, with a small amount of safe, traceable carbon to aid tracking. Researchers seek healthy men who weigh more than 50 kg (about 110 lbs) and have a body mass index (BMI) between 17.5 and 32. The trial will compare how the body absorbs and eliminates the medicine when taken orally versus when delivered directly into the bloodstream. Participants will engage in the study for about seven weeks, including pre- and post-study check-ups. As a Phase 1 trial, this research focuses on understanding how the treatment functions in people, offering participants the chance to be among the first to receive this new medicine.

The trial does not specify if you need to stop taking your current medications. However, since the study is for healthy volunteers and excludes those with significant medical conditions, it's likely that participants should not be on any regular medications.

Research has shown that PF-07799544 remains in the early stages of testing to assess its safety and effects. Earlier studies with cancer patients indicated that PF-07799544 was generally well-tolerated, though some experienced side effects like nausea and tiredness. These studies involved patients with advanced cancer, which might influence side effects differently than in healthy individuals.

This study is in the early phase of testing, meaning that while no major safety issues have been reported so far, the complete safety profile of the treatment is still being determined. In this trial, the medication is combined with a small amount of a safe, naturally occurring radioactive substance. This addition helps researchers track how the body absorbs and processes the medicine. The added radiation does not alter the medicine's function but aids researchers in observing its movement within the body.

PF-07799544 is unique because it uses a novel radioactive carbon-labeled compound, known as \[14C\] PF-07799544, to study how the body processes the drug. Unlike standard treatments, which typically focus on efficacy and safety, this approach allows researchers to closely track the drug's absorption, distribution, metabolism, and excretion. Researchers are excited about this treatment because it offers a detailed understanding of the drug's behavior in the body, potentially leading to more effective and safer dosing strategies in future therapeutic applications.

Research shows that PF-07799544 targets a protein called MEK, which contributes to cancer growth. This protein is crucial for cell division and survival, particularly in cancer cells. Studies have found that blocking MEK can slow or halt the growth of certain tumors. Although current data is limited, early results suggest that targeting the MEK protein could be a promising approach for treating cancers like melanoma, which involve changes in the BRAF gene, another protein that interacts with MEK. In this trial, researchers are testing PF-07799544 in healthy volunteers to assess its safety and pharmacokinetics.¹²⁵⁶⁷